REVIEW article
Front. Cell Dev. Biol.
Sec. Signaling
Volume 13 - 2025 | doi: 10.3389/fcell.2025.1632122
Interactions between Glioblastoma and Myeloid Cells
Provisionally accepted
Yuting Li1,2
Yuhong Chen3
Kai Cai1,2*
Yujuan Qin4
Xi Wang5Bo Zhang4Lin Shi4Zonglin He1,2Jiasheng Wang1,2Jiecun Long1,2Yishun Zeng1,2Qiong Gong1,2- 1Guangxi University of Chinese Medicine, Nanning, China
- 2First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, Guangxi Zhuang Region, China
- 3Department of Nephrology, Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Region, China
- 4Institute of Cardiovascular Sciences, The People’s Hospital of Guangxi Zhuang Autonomous Region & Guangxi Academy of Medical Sciences, Nanning, China,, Nanning, China
- 5School of Medicine, Guangxi University, Nanning, Guangxi Zhuang Region, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Standing as the most aggressive form of primary malignant tumor, Glioblastoma (GBM) tumors with marked heterogeneity represents one of the enormous challenges in glioma treatment. Myeloid cells, which includes neutrophils,myeloid-derived suppressor cells,microglia,and macrophages , play a pivotal role in the tumor microenvironment of GBM.In the tumor microenvironment (TME), T cells and natural killer (NK) cells exert anti-tumor functions, whereas myeloid-derived suppressor cells (MDSCs) can promote tumor progression by suppressing these immune responses. Therefore, MDSCs play a critical role in shaping the effectiveness of immunotherapy. TME has constrained the ability of traditional GBM treatment approaches to significantly enhance prognostic outcomes for patients. This category encompasses conventional therapies like surgical resection and radiation therapy, along with cutting-edge methodologies such as immunotherapy. Through extensive investigations into the dynamic interactions between the GBM microenvironment and neoplastic cells, both targeted treatment strategies and innovative immunotherapeutic modalities have emerged, offering promising new directions for clinical intervention.This review focuses on the interactions between GBM and myeloid cells (MCs), providing novel insights into the oncogenesis and progression of GBM.
Keywords: GBM, TAM, MDSC, TME, myeloid cells
Received: 20 May 2025; Accepted: 16 Jun 2025.
Copyright: © 2025 Li, Chen, Cai, Qin, Wang, Zhang, Shi, He, Wang, Long, Zeng and Gong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Kai Cai, Guangxi University of Chinese Medicine, Nanning, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.